Symbols

VALN

Valneva·NASDAQ

--(--)

VALN fundamentals

VALN Q4 2025 Earnings

Valneva (VALN) released its earnings on Feb 19, 2026: revenue was 54.62M (YoY -9.21%), beat estimates; EPS was -0.24 (YoY +50.67%), beat estimates.

Revenue / YoY

54.62M

-9.21%

EPS / YoY

-0.24

+50.67%

Report date

Feb 19, 2026

VALN Earnings Call Summary for Q4,2025

Lyme Vaccine Milestone: Phase 3 data expected mid-2026, targeting 500,000+ U.S. Lyme cases. Shigella vaccine trials underway, with potential 2026 data.
Financial Resilience: 2025 proprietary sales +9%, cash burn down 20%. 2026 guidance: EUR 145-160M sales, focusing on Lyme vaccine approval and Shigella trials.
Strategic Shift: Expanding into non-vector vaccines (e.g., EBV), with potential 2026 DoD contract renewal for IXIARO. Shigella trials in adults and children, with mid-2026 data.
Risk Management: Geopolitical vaccine hesitancy, but Lyme vaccine's prophylactic cost优势. Pfizer's control over phase 3, with Valneva blinded until approval.

Earnings

EPS

Revenue

Revenue & Expenses

VALN has released its 2025 Q4 earnings report, with revenue of 55.97M, reflecting a YoY change of 2.13%, and net profit of -58.70M, showing a YoY change of -53.33%. The Sankey diagram below clearly presents VALN's revenue sources and cost distribution.

Key Indicators

Valneva (VALN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Valneva (VALN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Valneva (VALN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Valneva (VALN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown